他米巴罗汀：AM 80、维甲酸、他米巴罗。

Tamibarotene: AM 80, retinobenzoic acid, Tamibaro.

出版信息

Drugs R D. 2004;5(6):359-62. doi: 10.2165/00126839-200405060-00010.

DOI:10.2165/00126839-200405060-00010

Abstract

Tamibarotene [AM 80, retinobenzoic acid, Amnoid, Tamibaro] is a novel synthetic retinoid that is in development with Nippon Shinyaku as a potential treatment for acute promyelocytic leukaemia (APL) and is pending approval in Japan. Tamibarotene was being developed by Shionogi in Japan but the company subsequently discontinued its involvement. Various nonindustrial sources, such as the University of Tokyo, Japan, have also played a role in the development of tamibarotene. Nippon Shinyaku has licensed the rights to tamibarotene from Toko Pharmaceutical Industries for the treatment of acute promyelocytic leukaemia, according to Nippon Shinyaku's June 2004 pipeline update. However it is unclear when Toko Pharmaceutical Industries acquired rights to the compound.

摘要

他米巴罗汀[AM 80、维甲酸、Amnoid、Tamibaro]是一种新型合成维甲酸，正由日本新药株式会社研发，作为急性早幼粒细胞白血病（APL）的潜在治疗药物，目前正在日本等待批准。他米巴罗汀此前由日本盐野义制药公司在日本进行研发，但该公司随后停止了相关工作。日本东京大学等各种非工业来源也在他米巴罗汀的研发过程中发挥了作用。根据日本新药株式会社2004年6月的产品线更新，该公司已从东光制药工业株式会社获得他米巴罗汀治疗急性早幼粒细胞白血病的许可权。然而，目前尚不清楚东光制药工业株式会社是何时获得该化合物的权利的。